ASX Announcements
Application for quotation of securities - PNV
Appendix 2A (Application for Quotation of Securities)
- Oct 4, 2024
- 6 pages
March
CBA needs growth to justify $119 price tag, says Fidelity
Fund manager Casey McLean believes Commonwealth Bank deserves to trade at a premium to its rivals and names a biotech stock flying under the radar.
- Joanne Tran
June 2023
‘Lateral thinking’: How to break into the US market
US roadshows are one way that Micro-X’s company’s lightweight portable X-ray machines are tapping into healthcare across the world.
- Christopher Niesche
- Exclusive
- Sharemarket
PolyNovo tipped to post record sales
The one-time small-cap darling is expected to implore investors to rethink its prospects after Wednesday’s bullish trading update.
- Tom Richardson
October 2022
Burns treatment biotech soars 22pc on record sales month
PolyNovo has surpassed $5 million in monthly sales for the first time after expanding its US sales team.
- Yolanda Redrup
September 2022
PolyNovo set for FDA clearance of new US product
PolyNovo was placed in a trading halt on Friday afternoon, pending an announcement regarding clearance by the US FDA for a ‘major new product’.
- Yolanda Redrup
August 2022
PolyNovo shares slide 18pc after earnings miss
PolyNovo’s revenue surged 42.8 per cent to $41.9 million in the last year, but it remains unprofitable.
- Yolanda Redrup
July 2022
PolyNovo soars after snaring J&J veteran as new CEO
Shares in burns treatment specialist PolyNovo bounced nearly 8 per cent on Friday afternoon after the announcement of a new CEO.
- Yolanda Redrup
November 2021
PolyNovo’s tumble, CEO’s exit leave room for improvement
The biotech appeared resilient to the headwinds of COVID-19, but the sudden exit of its CEO and more virus waves make the outlook hazy.
- Carrie LaFrenz
Regal’s Phil King was right on Polynovo ... eventually
Though being early is the same as being wrong, particularly when leverage is involved.
- Myriam Robin
Polynovo’s CEO resigns
Paul Brennan will remain as managing director for the next three months to assist with an orderly transfer of leadership.
- Tom Richardson
February 2021
PolyNovo sales growth slows as lockdowns hit surgery rates
Biotech company PolyNovo’s revenue grew 25.3 per cent for the first half, as it hit $12.8 million.
- Yolanda Redrup
Buy, hold, sell: Polynovo, Lynas, Pointsbet, EML, Zip
Livewire Markets has brought in the experts to get their take on your 2021 top-tipped small caps.
January 2021
PolyNovo says COVID-19 surge slowed US second quarter sales
The biotech says predicting sales trajectory in its key market is "challenging" with hospital capacity strained as COVID-19 cases surge.
- Updated
- Carrie LaFrenz
August 2020
PolyNovo sales prove resilient to COVID-19
Biotech PolyNovo's shares slipped more than 9 per cent on Wednesday, despite the company more than doubling sales of its flagship product.
- Yolanda Redrup
July 2020
ASX-aspirant Aroa set to list one week early
Market debutante Aroa Biosurgery will list one week earlier than expected after recording strong demand for its initial public offering.
- Sarah Thompson, Anthony Macdonald and Tim Boyd
April 2020
PolyNovo chief finally joins board
The next time Paul Brennan changes his holdings, he will be obliged to disclose it.
- Myriam Robin
Polynovo sales surge almost vindicates David Williams' top-ups
Since the results in late February, few days have gone by without Williams increasing his holdings
- Myriam Robin
PolyNovo sales surge despite coronavirus curbs
The biotech company said sales jumped in the March quarter and had not slowed due to the coronavirus.
- Yolanda Redrup
March 2020
The directors buying into their cratering companies
With trading windows wide open, some insiders have had the cash on hand to buy while the going is cheap.
- Myriam Robin
February 2020
‘No logical basis’ for share slump, says PolyNovo CEO
The biotech company is confident it will more than double sales of its burns and wounds scaffold in the 2020 full-year.
- Yolanda Redrup